Outlook Therapeutics
Open
$0.25
Prev. Close
$0.25
High
$0.25
Low
$0.25
Market Snapshot
$16.44M
-0.2
-4.62
17
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
emptyResult
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Recently from Cashu
Outlook Therapeutics Advances Ocular Treatments Amid Stable Market Sentiment and Strategic Collaborations
Outlook Therapeutics: Advancements in Ocular Treatments Amidst Stable Market Sentiment Outlook Therapeutics is making significant strides in the field of ocular treatments, particularly with its focus…
Outlook Therapeutics: Innovating Vision Treatments with ONS-5010 for AMD Patients
Outlook Therapeutics: Pioneering the Future of Vision-Correcting Treatments Outlook Therapeutics focuses on advancing therapies that target retinal diseases, particularly the treatment of wet age-rela…
Outlook Therapeutics (OTLK) Faces FDA Rejection of Lytenava, Impacting Future Prospects
Outlook Therapeutics Faces Regulatory Setback with FDA Rejection of Lytenava Outlook Therapeutics, Inc. experiences a significant challenge as the U.S. Food and Drug Administration (FDA) issues a seco…
Outlook Therapeutics’ Lytenava Faces FDA Rejection, Stock Hits New Low
Outlook Therapeutics Faces Regulatory Setback with FDA Rejection of Lytenava Outlook Therapeutics, Inc. faces a significant challenge following the U.S. Food and Drug Administration’s (FDA) recent rej…